Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of a Dexmedetomidine on Quality of Recovery 40 and Postoperative Nausea and Vomiting in Breast Cancer Surgery

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by Yonsei University.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Yonsei University Identifier:
First received: February 27, 2012
Last updated: July 19, 2012
Last verified: July 2012

Postoperative nausea and vomiting (PONV) is common following beast surgery. Dexmedetomidine was reported to a reduced PONV due to opioid-sparing effect. It is not clear if dexmedetomidine itself is useful on reducing PONV. The hypothesis of present study: intraoperative application of single dose dexmedetomidine (0.5 mcg/kg) is is effective than placebo for reducing of PONV and improve postoperative quality of recovery score within 48 postoperative hours.

Condition Intervention
Breast Cancer
Drug: Dexmedetomidine
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Official Title: Effects of a Single Dose Dexmedetomidine on Postoperative Nausea and Vomiting (PONV) and Quality of Recovery 40 (QoR 40) in Breast Cancer Surgery

Resource links provided by NLM:

Further study details as provided by Yonsei University:

Primary Outcome Measures:
  • Quality of Recovery 40 (QoR-40) [ Time Frame: 24 postoperative hours ] [ Designated as safety issue: Yes ]

    quality of recovery was determined by QOR-40 questionnaire.

    (all same as Dexmedetomidine group and Placebo group)

Secondary Outcome Measures:
  • Change from preoperative baseline in PONV within 48 postoperative hours [ Time Frame: every 6 hours within 48 postoperative hours ] [ Designated as safety issue: Yes ]

    PONV was determined by visual analogue scale, number of emetic episode every 6 hours within 48 postoperative hours

    (all same as Dexmedetomidine group and Placebo group)

Estimated Enrollment: 100
Study Start Date: September 2011
Estimated Study Completion Date: July 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group D
A single dose dexmedetomidine 0.5 mcg/kg iv. 30 min before end of the surgery
Drug: Dexmedetomidine
A single dose dexmedetomidine 0.5 mcg/kg IV. 30 min before end of the surgery
Placebo Comparator: Group P
Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
Drug: Placebo
Placebo 0.5 mcg/kg iv. 30 min before end of the surgery

Detailed Description:

This study was approved by the Institutional Review Board of Severance Hospital, Yonsei University Health System. After written informed consent was obtained from all patients, aged 20-75 years with ASA physical status class I-II who were scheduled breast cancer surgery under general anaesthesia were enrolled in this study All the patients were randomly assigned to receive dexmedetomidine or placebo during surgery. The primary outcome was quality of recovery determined by QOR-40 in the first 24h after surgery.The secondary outcome measure was PONV assessed by visual analogue scale every 6 hours within 48 postoperative hours.


Ages Eligible for Study:   20 Years to 60 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ASA I, II
  • aged 20-60 years
  • Undergoing breast cancer surgery

Exclusion Criteria:

  • CAOD
  • Bradycardia
  • QT prolongation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01548209

Contact: Yong Seon Choi, MD,PhD 82-2-2227-3556
Contact: Shin Hyung Kim, MD 82-2-2227-3556

Korea, Republic of
Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, 250 Seungsan-no, Seodaemun-gu Recruiting
Seoul, Korea, Republic of, 120-752
Contact: Yong Seon Choi, MD, PhD    82-2-2227-3556   
Contact: Shin Hyung Kim, MD, PhD    82-2-2227-3556   
Sponsors and Collaborators
Yonsei University
  More Information

No publications provided

Responsible Party: Yonsei University Identifier: NCT01548209     History of Changes
Other Study ID Numbers: 4-2011-0415
Study First Received: February 27, 2012
Last Updated: July 19, 2012
Health Authority: Korea: Food and Drug Administration

Additional relevant MeSH terms:
Breast Neoplasms
Postoperative Nausea and Vomiting
Breast Diseases
Neoplasms by Site
Pathologic Processes
Postoperative Complications
Signs and Symptoms
Signs and Symptoms, Digestive
Skin Diseases
Adrenergic Agents
Adrenergic Agonists
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Analgesics, Non-Narcotic
Central Nervous System Agents
Central Nervous System Depressants
Hypnotics and Sedatives
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on November 25, 2014